This brand name is authorized in United States
The drug TEPEZZA contains one active pharmaceutical ingredient (API):
|
1
Teprotumumab
UNII Y64GQ0KC0A - TEPROTUMUMAB
|
|
Teprotumumab’s mechanism of action in patients with Thyroid Eye Disease has not been fully characterized. Teprotumumab binds to IGF-1R and blocks its activation and signaling. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| TEPEZZA Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: US | FDA, National Drug Code | Identifier(s): 75987-130 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
